Literature DB >> 30304323

Survival-associated alternative splicing signatures in esophageal carcinoma.

Shuangshuang Mao1, Yuan Li1, Zhiliang Lu1, Yun Che1, Shouguo Sun1, Jianbing Huang1, Yuanyuan Lei1, Xinfeng Wang1, Chengming Liu1, Sufei Zheng1, Ruochuan Zang1, Ning Li1, Jiagen Li1, Nan Sun1, Jie He1.   

Abstract

Alternative splicing (AS), a major mechanism for the enhancement of transcriptome and proteome diversity, has been widely demonstrated to be involved in the full spectrum of oncogenic processes. High-throughput sequencing technology and the rapid accumulation of clinical data sets have provided an opportunity to systemically analyze the association between messenger RNA AS variants and patient clinical outcomes. Here, we compared differentially spliced AS transcripts between esophageal carcinoma (ESCA) and non-tumor tissues, profiled genome-wide survival-associated AS events in 87 patients with esophageal adenocarcinoma (EAC) and 79 patients with esophageal squamous cell carcinoma (ESCC) using The Cancer Genome Atlas (TCGA) RNA-seq data set, and constructed predictive models as well as splicing regulation networks by integrated bioinformatic analysis. A total of 2326 AS events in 1738 genes and 1812 AS events in 1360 genes were determined to be significantly associated with overall survival (OS) of patients in the EAC and ESCC cohorts, respectively, including some essential participants in the oncogenic process. The predictive model of each splice type performed reasonably well in distinguishing good and poor outcomes of patients with esophageal cancer, and values for the area under curve reached 0.942 and 0.815 in the EAC exon skip predictive model and the ESCC alternate acceptor site predictive model, respectively. The splicing regulation networks revealed an interesting correlation between survival-associated splicing factors and prognostic AS genes. In summary, we created prognostic models for patients with esophageal cancer based on AS signatures and constructed novel splicing correlation networks.
© The Author(s) 2018. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2019        PMID: 30304323     DOI: 10.1093/carcin/bgy123

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  23 in total

1.  Alterations of RNA splicing patterns in esophagus squamous cell carcinoma.

Authors:  Jiyu Ding; Chunquan Li; Yinwei Cheng; Zepeng Du; Qiuyu Wang; Zhidong Tang; Chao Song; Qiaoxi Xia; Wenjing Bai; Ling Lin; Wei Liu; Liyan Xu; Enmin Li; Bingli Wu
Journal:  Cell Biosci       Date:  2021-02-09       Impact factor: 7.133

2.  Prognostic alternative splicing signatures and underlying regulatory network in esophageal carcinoma.

Authors:  Zu-Cheng Xie; Hua-Yu Wu; Fu-Chao Ma; Yi-Wu Dang; Zhi-Gang Peng; Hua-Fu Zhou; Gang Chen
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

3.  Genome-Wide Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Esophageal Carcinoma.

Authors:  Jian-Rong Sun; Chen-Fan Kong; Yan-Ni Lou; Ran Yu; Xiang-Ke Qu; Li-Qun Jia
Journal:  Front Genet       Date:  2020-07-22       Impact factor: 4.599

4.  Genome-wide profiling of prognosis-related alternative splicing signatures in sarcoma.

Authors:  Weifeng Hong; Weicong Zhang; Renguo Guan; Yuying Liang; Shixiong Hu; Yayun Ji; Mouyuan Liu; Hai Lu; Min Yu; Liheng Ma
Journal:  Ann Transl Med       Date:  2019-10

5.  Characterization of alternative splicing events and prognostic signatures in breast cancer.

Authors:  Pihua Han; Jingjun Zhu; Guang Feng; Zizhang Wang; Yanni Ding
Journal:  BMC Cancer       Date:  2021-05-22       Impact factor: 4.430

6.  The landscape and biological relevance of aberrant alternative splicing events in esophageal squamous cell carcinoma.

Authors:  Quanyou Wu; Yuan Zhang; Haiyin An; Wei Sun; Ruozheng Wang; Meng Liu; Kaitai Zhang
Journal:  Oncogene       Date:  2021-06-02       Impact factor: 9.867

7.  Study on the Selection of the Targets of Esophageal Carcinoma and Interventions of Ginsenosides Based on Network Pharmacology and Bioinformatics.

Authors:  Xin Yang; Yahui Li; Haibing Qian
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-24       Impact factor: 2.629

8.  Alternative splicing associated with cancer stemness in kidney renal clear cell carcinoma.

Authors:  Lixing Xiao; Guoying Zou; Rui Cheng; Pingping Wang; Kexin Ma; Huimin Cao; Wenyang Zhou; Xiyun Jin; Zhaochun Xu; Yan Huang; Xiaoyu Lin; Huan Nie; Qinghua Jiang
Journal:  BMC Cancer       Date:  2021-06-15       Impact factor: 4.430

9.  Systematic Profiling of mRNA Splicing Reveals the Prognostic Predictor and Potential Therapeutic Target for Glioblastoma Multiforme.

Authors:  Botao Zhang; Quanyou Wu; Shujun Cheng; Wenbin Li
Journal:  J Oncol       Date:  2021-07-05       Impact factor: 4.375

10.  Prognostic alternative mRNA splicing signatures and associated splicing factors in acute myeloid leukemia.

Authors:  Peng Jin; Yun Tan; Wei Zhang; Junmin Li; Kankan Wang
Journal:  Neoplasia       Date:  2020-07-09       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.